Lipanthyl-267 M (Fenofibrate) is commonly used in situations involving long-term management of chronic dyslipidemias, focusing on addressing specific abnormalities in blood lipid levels that may be associated with increased systemic burden. It is applied when therapeutic lifestyle changes alone are insufficient to achieve target lipid goals. Its use is guided by specific lipid profiles.

The medication primarily addresses conditions such as severe elevation of plasma triglycerides, mixed dyslipidemia, and atherogenic dyslipidemia (a pattern marked by high triglycerides and low protective HDL-C). By assisting with managing these fats, it plays a role in managing the overall lipid profile. This is relevant for patient groups including adults with primary dyslipidemia and those with co-existing conditions like Type 2 Diabetes Mellitus and Metabolic Syndrome.

Therapy in this context is often relevant for supporting the patient during chronic metabolic challenges by managing key lipid risk factors. A significant benefit of this therapy, especially in cases of very high triglycerides, is that it may assist with managing the risk of acute pancreatitis.

---

Quick Fact: Relief for Lipid Profile Management

This treatment supports general well-being by managing the specific abnormalities (high triglycerides and low HDL-C) that create noticeable physiological strain.

Eligibility to Use Lipanthyl-267 M (Fenofibrate)

This section outlines the specific populations, medical conditions, and physiological states where the use of Lipanthyl-267 M (fenofibrate) is either permitted, contraindicated (strictly prohibited), or requires special consideration, based on official regulatory labeling.

Contraindications and Prohibited Use

Use of this medication is contraindicated (must not be taken) in patients with:

• Severe renal impairment (kidney disease).
• Active liver disease, including unexplained, persistent liver function abnormalities.
• Known gallbladder disease.
• Chronic or acute pancreatitis (unless the acute condition is due to very high triglyceride levels).
• Known hypersensitivity or allergic reactions to fenofibrate or to other fibrates/ketoprofen involving photoallergy.
• Breastfeeding women.

Restricted and Non-Recommended Use

• Children and Adolescents (under 18 years): Use is not recommended as safety and effectiveness have not been established.
• Mild-to-Moderate Renal Impairment: Patients must use a reduced dose and be closely monitored.
• Pregnancy: Use is generally not recommended or should only occur if the potential benefit outweighs the risk to the fetus.
• Hepatic Impairment: Use is not recommended due to a lack of data.

Interactions with other medicines and products

Lipanthyl-267 M (Fenofibrate) has officially documented interaction patterns that influence how it can be co-administered with specific medicinal products, primarily classified as pharmacodynamic and pharmacokinetic interactions as defined in regulatory labeling.

---

Documented Interaction Patterns

Interacting Product Category	Official Regulatory Outcome/Restriction
HMG-CoA Reductase Inhibitors (Statins)	Increased risk of myopathy and rhabdomyolysis (additive muscle toxicity risk).
Coumarin Anticoagulants (e.g., Warfarin)	Potentiation of anticoagulant effects, requiring frequent monitoring of PT/INR. Fenofibric acid may increase the concentration of free, active Warfarin.
Bile Acid Sequestrants (Resins)	Reduced Fenofibrate absorption, necessitating a mandatory dose separation rule.
CYP2C9 Substrates (e.g., Glimepiride)	Fenofibric acid is a mild-to-moderate inhibitor of CYP2C9, leading to increased exposure (AUC) of the co-administered drug.
Immunosuppressants (e.g., Cyclosporine)	Documented increased risk of renal deterioration.

---

Administration Requirements and Specific Notes

Co-administration with Bile Acid Sequestrants mandates that Fenofibrate must be taken at least 1 hour before or 4 to 6 hours after the resin to prevent absorption interference. The risk of muscle toxicity is officially noted to be increased in geriatric patients and those with renal impairment when Fenofibrate is co-administered with a statin. Furthermore, the absorption of the Fenofibrate capsule is enhanced when taken with food.

Genomic Regulation through PPAR-Alpha Activation

The core action of Fenofibrate begins at the cellular nucleus, where its active metabolite acts as a high-affinity agonist for the Peroxisome Proliferator-Activated Receptor Alpha (PPAR-alpha). By activating this master regulator, the drug directly controls the transcription (gene expression) of key enzymes and proteins involved in fat metabolism, leading to a coordinated change in systemic lipid balance.

---

Accelerating the Catabolism of Circulating Fats

A key mechanistic consequence of PPAR-alpha activation is the increased catabolism of triglyceride-rich lipoproteins in the plasma. This is achieved by increasing the production of Lipoprotein Lipase (LPL)—the enzyme responsible for hydrolyzing triglycerides in VLDL and chylomicrons—while simultaneously repressing Apolipoprotein C-III (ApoC-III), a natural LPL inhibitor. This cascade results in the physiological effect of accelerated plasma triglyceride clearance.

---

Remodeling Cholesterol Particles (HDL/LDL)

The mechanism also modulates the reverse cholesterol transport pathway by increasing the synthesis of Apolipoprotein A-I (ApoA-I), a key structural component of High-Density Lipoprotein (HDL). Furthermore, Fenofibrate reduces the expression of CETP, which results in the remodeling of cholesterol carriers. This action produces a physiological adjustment toward an increase in circulating HDL cholesterol and an altered distribution of other cholesterol particles.

Fenofibrate, the active ingredient in Lipanthyl-267 M, is officially administered as a hard capsule for the long-term management of dyslipidemia under specific regulatory guidelines. The medicine is intended for oral administration and must be taken once daily.

The standard adult dosing regimen for primary hypercholesterolemia or mixed dyslipidemia is 150 mg once per day, which also represents the maximum recommended daily amount for this formulation. To ensure the proper and consistent systemic absorption of the micro-ionized formulation, the capsule must be administered with meals.

It is a crucial administration requirement that the hard capsule be swallowed whole and must not be crushed, opened, or chewed. If the patient is also taking a bile acid binding resin, Fenofibrate must be consumed with a significant time separation, specifically at least one hour before or four to six hours after the resin.

Specific adjustments to the starting dose are required for certain adult populations; for instance, therapy must be initiated at a reduced dose, such as 50 mg once daily (or equivalent), for patients diagnosed with mild-to-moderate renal impairment. The dosage is then subject to adjustment following periodic evaluation of lipid response, typically assessed every four to eight weeks. In the event of a missed dose, an extra dose should never be taken; the patient should simply resume the regular once-daily schedule.

Research Evidence / Overview of Studies for Lipanthyl-267 M

This overview describes the types of clinical studies that have been conducted on Fenofibrate, the active ingredient in Lipanthyl-267 M, and the scope of the evidence available from authoritative sources. It focuses on what research examined and what patterns were observed in the studied populations, without offering medical advice or treatment recommendations.

---

Evidence for Managing Severely Elevated Triglycerides

This section summarizes the evidence base that informs the research context for using Lipanthyl-267 M in patients with very high blood triglyceride levels (e.g., ge 500 mg/dL), in the research context examining the relationship to potential acute risks.

Research has explored the use of this medicine in adults with severe primary hypertriglyceridemia. Studies monitored the impact of the medicine on the target biomarker, serum Triglyceride (TG) levels. The main rationale for the research in this area is to explore the relationship to the risk associated with acute pancreatitis.

Findings describe patterns observed in the studies where there were consistent reports of patterns related to lower serum TG levels in the observed populations. What remains uncertain is the full scope of evidence from dedicated, long-term Randomized Controlled Trials (RCTs) specifically designed to use the incidence of acute pancreatitis as the primary clinical outcome.

---

Evidence from Large Trials on Lipid Profile and Cardiovascular Outcomes

This section details the outcomes measured in the largest and longest Randomized Controlled Trials (RCTs) that have examined the medicine's association with mixed dyslipidemia and the major cardiovascular events (such as non-fatal heart attack or stroke) that the research examined.

Focus on Consistent Lipid Biomarker Shifts

Research consistently highlights changes measured during the study period, including patterns related to lower TG levels and observed shifts in HDL-C levels. However, when trials monitored the incidence of major composite cardiovascular events, findings were mixed.

The research generally describes that the overall pattern related to these long-term clinical outcomes was neutral across the broad populations in the largest RCTs. The primary limitation in the current research is that the largest, longest, and most robust studies reported a neutral overall pattern related to the primary clinical outcome of major cardiovascular events for the entire population studied.

---

Common questions about Lipanthyl-267 M (FAQ)

---

Q: Is it true that Lipanthyl-267 M only works if you change your diet?

A: Official product information describes Lipanthyl-267 M as adjunctive therapy to diet. This means the medicine is intended to be used in addition to an appropriate lipid-lowering diet. Patients are generally advised to continue their dietary regimen throughout the course of treatment.

Q: What happens if I stop taking Lipanthyl-267 M suddenly?

A: Regulatory documents do not describe specific adverse events when the medicine is stopped abruptly in patients who are responding well. Treatment should only be withdrawn if there is an inadequate response or when directed by a healthcare provider. Regulatory guidance suggests that any discontinuation of a prescribed medicine be discussed with a healthcare provider.

Q: Are there any long-term side effects from taking Lipanthyl-267 M?

A: Official documentation cites risks associated with prolonged treatment, including the potential for cholelithiasis (gallstone formation), which is linked to increased cholesterol excretion into the bile. Healthcare providers require periodic monitoring of liver and kidney function during long-term use.

Q: Why is it important to have regular blood tests while taking Lipanthyl-267 M?

A: Regulatory documents require regular blood tests for two main purposes. The first is to monitor liver and renal function to check for potential adverse effects on these organs. The second is to check your blood lipid levels to assess how the medicine is affecting your lipid profile and to determine if any dosage adjustment is needed.

Q: Does Lipanthyl-267 M improve 'good' cholesterol (HDL)?

A: Yes, regulatory documents indicate that Fenofibrate, the active ingredient, is intended to increase high-density lipoprotein cholesterol (HDL-C) in adult patients. HDL-C is often referred to as 'good' cholesterol because of its role in transporting cholesterol away from the arteries.

Q: Why might a doctor choose Lipanthyl-267 M over a lower strength?

A: Official labeling states that the dosage should be individualized based on the patient's specific condition and response to treatment. A prescriber selects the specific dosage unit, such as 267 mg, as part of the strategy to reach and maintain the patient’s targeted lipid levels.

Q: What are the typical expected benefits from taking Lipanthyl-267 M?

A: The medicine is officially indicated for correcting abnormal lipid levels in the blood. This generally involves reducing elevated levels of total cholesterol, LDL-C, triglycerides, and Apo B. A concurrent goal is to increase levels of HDL-C in patients with primary hypercholesterolemia or mixed dyslipidemia.

Q: Why is this specific strength of 267 M used?

A: The 267 mg strength is associated with a specific, proprietary micro-ionized formulation of the capsule. This specialized formulation uses a micro-ionized particle size which is intended to provide consistent and appropriate absorption of the active ingredient, Fenofibrate, into the bloodstream.

Q: Does Lipanthyl-267 M accelerate or delay the onset/effect of other medicines?

A: Regulatory documents report that Fenofibrate can potentiate the effects of coumarin anticoagulants (like Warfarin), which may increase their activity and the risk of bleeding. The medicine may also increase the exposure of other co-administered drugs that are processed by the CYP2C9 enzyme in the body.

Q: Is it normal to feel slightly nauseous when starting Lipanthyl-267 M?

A: Nausea is categorized as a common adverse reaction in the regulatory labeling for Fenofibrate. This means the symptom has been reported in 1 % to 10 % of patients during clinical data collection, which may be more noticeable when first starting the medication.

Q: Can Lipanthyl-267 M affect sleep?

A: Official adverse reaction reporting lists insomnia (difficulty sleeping) as a common side effect. This means that sleep disturbances have been reported in 1 % to 10 % of patients receiving this medication in clinical studies.

Q: Are there different forms of Lipanthyl-267 M (e.g., tablet vs capsule)?

A: The specific product, Lipanthyl-267 M, is officially supplied for oral administration as a hard capsule. While Fenofibrate, the active ingredient, is available in other tablet and capsule forms under different brand names, this specific product uses the micro-ionized capsule formulation.

Q: Does Lipanthyl-267 M cause weight gain or loss?

A: Changes in body weight are not listed as a common or uncommon side effect in the primary regulatory labeling. However, documentation describing signs of serious liver problems sometimes mentions weight loss as a symptom requiring investigation.

Q: Is there a maximum time someone can stay on Lipanthyl-267 M?

A: The labeling does not define a maximum duration of treatment; therapy for lipid disorders is typically long-term. However, regulatory guidelines state that if a patient does not demonstrate an adequate response in their blood lipid levels after two months, the therapy should be withdrawn.

Q: How is Lipanthyl-267 M different from other fibrates?

A: The regulatory documents for Fenofibrate mention a specific safety point regarding its co-administration with statins. Fenofibrate is generally noted to have a lower documented risk of muscle toxicity (rhabdomyolysis) when used alongside statins, compared to another drug in the same fibrate class, gemfibrozil.

Q: Does Lipanthyl-267 M require a special diet, like low-fat or low-carb?

A: The medicine is indicated as an adjunct to an appropriate lipid-lowering diet, but the regulatory text does not mandate a specific type (e.g., low-fat or low-carb). Official information does note that factors such as excess body weight and high alcohol intake should also be addressed during treatment.

Q: Is it true that Lipanthyl-267 M helps reduce the risk of pancreatitis in some cases?

A: The drug is prescribed for severe hypertriglyceridemia, a condition that is associated with an increased risk of pancreatitis. However, the regulatory labeling explicitly states that the effect of Fenofibrate therapy on reducing this specific risk has not been adequately studied or established.

Q: Can Lipanthyl-267 M be used for high lipid levels that run in the family?

A: The medicine is indicated for the treatment of primary hypercholesterolemia or mixed dyslipidemia in adults. These official categories encompass lipid disorders that can have a hereditary component, but the labeling does not list 'familial hyperlipidemia' as a separate, stand-alone indication.

Q: Can I take Lipanthyl-267 M with blood pressure medicine?

A: The official label does not restrict the use of all blood pressure medicines. However, it does note that certain medications often used to treat blood pressure, such as thiazide diuretics and beta-blockers, can sometimes be associated with increases in plasma triglycerides.

Q: Can Lipanthyl-267 M interact with supplements like fish oil?

A: Specific interactions with fish oil supplements (omega-3 fatty acids) are not listed in the primary regulatory drug interaction sections. However, official information generally recommends caution with omega-3 preparations in patients who have hepatic impairment (liver problems).

Q: Is Lipanthyl-267 M safe for older adults (seniors)?

A: Regulatory guidelines state that the dosage for older adults should be selected carefully based on the patient’s renal function, as kidney function can decline with age. It is also noted that the risk of muscle toxicity is higher for geriatric patients when the drug is co-administered with statins.

Q: Does Lipanthyl-267 M affect how well other medications are absorbed?

A: The medicine's active metabolite can inhibit the enzyme CYP2C9, which affects how the body breaks down (metabolizes) many other drugs. However, the regulatory text does not make a general claim that it affects the absorption of all other medications.

Q: Does Lipanthyl-267 M require a specific time of day for administration?

A: The medicine should be taken once daily and must be administered with meals to ensure proper absorption. Regulatory labeling does not mandate a specific time of day, such as morning or evening.

Q: Is there a risk of developing a new medical condition while on Lipanthyl-267 M?

A: Regulatory documents list several possible serious adverse reactions to the medicine. These include the potential development of conditions like pancreatitis, venous thromboembolism (blood clots), and the formation of gallstones (cholelithiasis).

Storage and Disposal of Lipanthyl-267 M (Fenofibrate)

Official regulatory labeling dictates strict requirements for storing and discarding Lipanthyl-267 M (fenofibrate 267 mg hard capsules) to ensure product stability and safety.

---

Mandatory Storage Conditions

Constraint	Requirement
Temperature	Do not store above 30 C.
Protection	Store in the original package to protect the contents.
Child Safety	Keep out of the sight and reach of children.

---

Disposal Instructions

Any unused or expired Lipanthyl-267 M medicinal product or waste material must be disposed of in accordance with local requirements. This instruction directs users to follow established pharmaceutical waste handling procedures in their specific region.